Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: fixed dose combination therapies - Celator

Drug Profile

Research programme: fixed dose combination therapies - Celator

Alternative Names: AUY 922/docetaxel - Celator Pharma; CPX-571; Docetaxel/luminespib - Celator Pharma; Ipatasertib/selumetinib - Celator Pharma; Targeted cancer therapies: Celator Pharma

Latest Information Update: 16 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celator Pharmaceuticals
  • Class
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis modulators; DNA cross linking agents; DNA synthesis inhibitors; DNA topoisomerase I inhibitors; Extracellular signal-regulated MAP kinase inhibitors; Histone acetyltransferase inhibitors; Histone deacetylase inhibitors; Mitogen-activated protein kinase kinase inhibitors; MTOR protein inhibitors; Proto oncogene protein c-akt inhibitors; Raf kinase inhibitors; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • No development reported Cancer; Head and neck cancer; Lung cancer

Most Recent Events

  • 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
  • 28 Aug 2018 No recent reports of development identified for research development in Cancer in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Head-and-neck-cancer in Canada (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top